METASTATIC PANCREATIC ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to extend life in tough pancreatic cancer
Disease control OngoingThis study looks at whether adding the immunotherapy drug pembrolizumab to the standard drug olaparib works better than olaparib alone for people with metastatic pancreatic cancer who have inherited BRCA1 or BRCA2 mutations. About 88 participants will be randomly assigned to one …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:19 UTC
-
Targeted drug combo shows promise for genetic pancreatic cancer
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemotherapy (gemcitabine and cisplatin) works better than chemotherapy alone for people with advanced pancreatic cancer who have a BRCA or PALB2 gene mutation. About 83 participants will receive either the combinatio…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
New hope for tough pancreatic cancer: targeted drug plus chemo shows promise
Disease control OngoingThis early-stage study tests a new drug, zolbetuximab, combined with standard chemotherapy in people with advanced pancreatic cancer that has spread. The drug targets a protein on cancer cells to help the immune system attack them. The main goals are to check safety and find the …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
Triple-Drug cocktail targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 people with advanced pancreatic cancer that had spread or could not be removed by surgery. The main goal was to find the safest dose and check for side effects. Researchers al…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New drug combo shows promise in tough pancreatic cancer trial
Disease control OngoingThis study tests whether adding zolbetuximab (a drug that targets a protein called CLDN18.2 found in many pancreatic tumors) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 393 adults whose cancer has spread and has the CLDN18.2 marker w…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug cocktail aims to starve pancreatic tumors
Disease control OngoingThis early-phase study tests a combination of two drugs—calaspargase pegol-mknl and cobimetinib—in people with advanced pancreatic cancer that has spread. The goal is to find the safest dose and see if the combo can control the disease by cutting off the cancer cells' food supply…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase study tested a new drug called sEphB4-HSA combined with standard chemotherapy in 61 people with advanced or metastatic solid tumors (like head and neck, pancreatic, lung, and gallbladder cancers). The goal was to find the best dose and check for side effects. Whi…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The goal is to find the best dose and see if the combination is safe and can shrink tumors. About 55…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New study aims to find best chemo for seniors with advanced pancreatic cancer
Disease control OngoingThis study compares two chemotherapy regimens in 176 older patients whose pancreatic cancer has spread. One group gets gemcitabine plus nab-paclitaxel; the other gets a combination of 5-FU, leucovorin, and liposomal irinotecan. The goal is to see which treatment helps patients li…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New hope for pancreatic cancer: drug combo aims to extend remission
Disease control OngoingThis study tests whether adding ivaltinostat to the chemotherapy drug capecitabine can help keep metastatic pancreatic cancer from growing. It is for people whose cancer has not worsened after initial treatment with FOLFIRINOX. The study has two parts: first finding the best dose…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: CG Pharmaceuticals, Inc • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New hope for pancreatic cancer: experimental drug DZ-002 enters phase 2 trial
Disease control ENROLLING_BY_INVITATIONThis study tests a new drug called DZ-002 in adults with metastatic pancreatic cancer that has not spread through families. Participants have already completed at least 4 months of standard chemotherapy and their disease is stable. The drug is given weekly through an IV in 4-week…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Hoag Memorial Hospital Presbyterian • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Enzyme pills aim to fight weight loss in advanced pancreatic cancer
Symptom relief OngoingThis study tests whether taking pancreatic enzyme pills (pancrelipase) can help people with metastatic pancreatic cancer maintain or gain weight. The study includes 17 participants who are starting chemotherapy. Researchers will compare two different dosing schedules and measure …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated May 26, 2026 03:54 UTC